Lilly to focus on new drugs in China, unload antibiotics brands and manufacturing facility for $375M

23rd April 2019 Uncategorised 0

Eli Lilly is taking one step out of China so it can gain a firmer foothold with the other. Citing an intention to focus on newer therapies, the U.S. pharma is selling Chinese rights to two legacy antibiotics and a manufacturing facility in a deal worth $375 million.

More: Lilly to focus on new drugs in China, unload antibiotics brands and manufacturing facility for 5M
Source: fierce